In a groundbreaking move within the pharmaceutical industry, Enveric Biosciences (NASDAQ: ENVB) a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, has announced a potentially transformative collaboration with MindBio Therapeutics (CNSX: MBIO)(“MindBio”) a clinical stage biopharma company, which is pioneering novel treatments for psychiatric conditions using microdoses of psychedelic medicines.
